A potent new opioid called Dsuvia that has not yet hit the market has already received a thumbs-down from the Official Disability Guidelines.
ODG by MCG has designated Dsuvia as “not recommended as a first line therapy for acute or chronic pain.” That means Dsuvia will be an “N” drug in the ODG drug formulary, which is used as the basis of workers’ comp prescription drug formularies in several states.
Dsuvia is a 30 microgram sufentanil tablet that is administered sublingually, or under the tongue, by a single-dose, pre-filled applicator. It is intended to treat...
Comments